Company: REVB
Filing Date: 2025-05-29
Form Type: PRE 14A
Source: 0000950170-25-078948
Chunk: 13

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-29
Form: PRE 14A
Chunk 13
---
S THAT YOU VOTE “FOR” THE NOMINEE LISTED ABOVE AS DIRECTOR OF THE COMPANY.

8</div>

Information about Our Directors Set forth below is certain information regarding the directors of the Company, including the nominees for election at the Annual Meeting and their ages as of May 29 , 2025 .

| Name                      |     | Age |     | Class |     | Director Since |     | Position                             |
| Jennifer Carver, BSN, MBA |     |  71 |     | A     |     |           2020 |     | Independent Director                 |
| James Rolke               |     |  56 |     | B     |     |           2020 |     | Director and Chief Executive Officer |
| Jess Roper                |     |  60 |     | B     |     |           2023 |     | Independent Director                 |
| Lakhmir Chawla, M.D.      |     |  54 |     | C     |     |           2023 |     | Independent Director                 |

Class A Directors Continuing in Office Until the 2026 Annual Meeting Jennifer Carver, BSN, MBA — Director. Ms. Carver has been a director of the Company since May 2020. Ms. Carver brings over 20 years of industry experience with a focus on small biotech companies and their evolution from early development through commercialization. From 2020 to 2021, Ms. Carver has served as Chief Operating Officer at Kartos Therapeutics (Kartos). Prior to Kartos from 2014, Ms. Carver was employed at La Jolla Pharmaceutical Company in various leadership roles providing leadership through the clinical development, approval and launch of Giapreza and serving as Chief Operating Officer from 2017 to 2019. Prior to La Jolla, Ms. Carver held positions at Spectrum Pharmaceuticals and Allos Therapeutics, leading teams through the development and approval of Belionostat and Folotyn respectively. Her experience in the healthcare industry spans multiple therapeutic areas including oncology, inflammatory disease, shock, iron overload, and anti-infectives. Ms. Carver has played a critical role in negotiating key alliances, evaluation of financing opportunities, and overseeing rapid organizational growth. Ms. Carver earned her B.S.N. and M.B.A. from University of Colorado. We believe that Ms. Carver’s extensive experience working in the biotechnology industry makes her well-qualified to serve as a